NRx Pharmaceuticals Set to Release Q1 2025 Financial Results and Provide Corporate Update
NRx Pharmaceuticals will disclose its first quarter 2025 financial performance and host a conference call, offering insights into its ongoing clinical-stage therapeutics development for central nervous system disorders.
NRx Pharmaceuticals (NASDAQ: NRXP) will release its first quarter 2025 financial results after market close on Thursday, May 15, 2025, with a subsequent conference call scheduled for 4:30 p.m. ET to discuss the results and provide a comprehensive corporate update.
The pharmaceutical company is currently developing innovative therapeutics targeting central nervous system disorders, focusing on critical areas such as suicidal bipolar depression, chronic pain, and post-traumatic stress disorder (PTSD). Its lead investigational therapy, NRX-101, has been designated a Breakthrough Therapy by the FDA and shows potential for treating suicidal treatment-resistant bipolar depression and chronic pain.
In a significant development, NRx has initiated a New Drug Application filing for NRX-100 (IV ketamine) to treat suicidal depression. This application is supported by well-controlled clinical trials conducted under the US National Institutes of Health and recent data from French health authorities. The company has also received Fast Track Designation from the FDA for ketamine development as part of a protocol to address acute suicidality.
Investors and industry observers can anticipate detailed insights into the company's strategic progress, research developments, and financial performance during the upcoming conference call, which represents a critical opportunity to understand NRx Pharmaceuticals' trajectory in addressing complex neurological conditions.